# EDGAR Filing Document

**Accession Number:** 0002023016
**File Stem:** 0001104659-25-097589
**Filing Date:** 2025-10
**Character Count:** 29976
**Document Hash:** d6b16aeb1132e94e17cbc3a7ee24da8d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-097589.hdr.sgml**: 20251007

**ACCESSION NUMBER**: 0001104659-25-097589

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20251007

**DATE AS OF CHANGE**: 20251007

**EFFECTIVENESS DATE**: 20251007

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Turn Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0002023016
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 320456090
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-290762
- **FILM NUMBER:** 251380735

**BUSINESS ADDRESS:**
- **STREET 1:** 250 NORTH WESTLAKE BLVD.
- **STREET 2:** #210
- **CITY:** WESTLAKE VILLAGE
- **STATE:** CA
- **ZIP:** 91362
- **BUSINESS PHONE:** 8185644011

**MAIL ADDRESS:**
- **STREET 1:** 250 N. WESTLAKE BLVD.
- **STREET 2:** #210
- **CITY:** WESTLAKE VILLAGE
- **STATE:** CA
- **ZIP:** 91362

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Global Health Solutions, Inc
- **DATE OF NAME CHANGE:** 20240510

**As filed with the Securities and Exchange Commission on October 7, 2025**

**Registration No._____**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT UNDER**

**THE SECURITIES ACT OF 1933**

**Turn Therapeutics Inc.**

(Exact Name of Registrant as Specified in Its Charter)

---

| | |
|:---|:---|
| **Delaware** | **32-0456090** |
| (State or Other Jurisdiction of<br> Incorporation or Organization) | (I.R.S. Employer Identification<br> No.) |
| **250 N. Westlake Blvd.**<br> **Westlake Village, California** | **91362** |
| (Address of Principal Executive Offices) | (Zip Code)  |

---

**Turn Therapeutics Inc. 2025 Omnibus Incentive Plan<br> Global Health Solutions Inc. 2024 Equity Incentive Plan**

**Global Health Solutions Inc. 2018 Stock Plan**

(Full Title of the Plans)

**Bradley Burnam <br> Chief Executive Officer <br> 250 N. Westlake Blvd. <br> Westlake Village, CA, 91362** <br> (Name and Address of Agent For Service)

**(818) 564-4011** <br> (Telephone Number, Including Area Code, of Agent for Service)

*Copies to:*

**Michael Kaplan <br> Stephen A. Byeff <br> Davis Polk & Wardwell LLP<br> 450 Lexington Avenue<br> New York, New York 10017<br> (212) 450-4000** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ◻ Accelerated filer ◻ <br> Non-accelerated filer ⌧ Smaller reporting company ⌧ <br> Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement on Form S-8 (this "Registration Statement") in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the "Securities Act"), and the introductory note to Part I of the Form S-8 instructions. The documents containing the information specified in Part I will be delivered to the participants in the plans as required by Rule 428(b)(1).

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The following documents filed by Turn Therapeutics Inc. (the "Registrant") with the Securities and Exchange Commission (the "Commission") pursuant to the Securities Exchange Act of 1934, as amended (the "Exchange Act"), are incorporated by reference herein:

&nbsp;&nbsp;&nbsp;&nbsp;(1) The Registrant's registration statement on [Form S-1 (File No. 333-289972), originally filed by the Registrant with the Commission on September 2, 2025](https://www.sec.gov/Archives/edgar/data/2023016/000110465925090474/tm2518292-7_s1a.htm) , as subsequently amended;

&nbsp;&nbsp;&nbsp;&nbsp;(2) All reports filed pursuant to Section 13(a) or 15(d) of
 the Securities Exchange Act of 1934, as amended (the "Exchange Act") since the
 end of the fiscal year covered by the Registrant's Registration Statement on the Form S-1
 referred to in clause (1) above; and

&nbsp;&nbsp;&nbsp;&nbsp;(3) The description of the Registrant's capital stock which is
 contained in the Registrant's Registration Statement on [Form 8-A (File No. 001-42875), filed by the Registrant with the Commission on September 29, 2025](https://www.sec.gov/Archives/edgar/data/2023016/000110465925094385/tm2518292d16_8a12b.htm) , including any amendments or supplements thereto.

In addition, all documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, after the date of this Registration Statement and prior to the filing of a post-effective amendment that indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, are incorporated by reference in this Registration Statement and are a part hereof from the date of filing of such documents; except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under current Items 2.02 or 7.01 of Form 8-K that is not deemed filed under such provisions. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 4. Description of Securities.**

Not applicable.

**Item 5. Interests of Named Experts and Counsel.**

Not applicable.

**Item 6. Indemnification of Directors and Officers.**

Section 145 of the Delaware General Corporation Law provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any threatened, pending or completed actions, suits or proceedings in which such person is made a party by reason of such person being or having been a director, officer, employee or agent to the Registrant. The Delaware General Corporation Law provides that Section 145 is not exclusive of other rights to which those seeking indemnification may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise. The Registrant's amended and restated certificate of incorporation and amended and restated bylaws will provide for indemnification by the Registrant of its directors, officers and employees to the fullest extent permitted by the Delaware General Corporation Law. The Registrant has entered into indemnification agreements with each of its current directors and officers to provide these directors and executive officers additional contractual assurances regarding the scope of the indemnification set forth in the Registrant's amended and restated certificate of incorporation and amended and restated bylaws and to provide additional procedural protections. There is no pending litigation or proceeding involving a director or executive officer of the Registrant for which indemnification is sought.

Section 102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director or officer of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, except for liability (i) for any breach of the director's or officer's duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) for a director for unlawful payments of dividends or unlawful stock repurchases, redemptions or other distributions, (iv) for any transaction from which the director or officer derived an improper personal benefit or (v) for an officer in any action by or in the right of the corporation. The Registrant's amended and restated certificate of incorporation provides for such limitation of liability.

The Registrant maintains standard policies of insurance under which coverage is provided (a) to its directors and officers against loss rising from claims made by reason of breach of duty or other wrongful act, and (b) to the Registrant with respect to payments which may be made by the Registrant to such officers and directors pursuant to the above indemnification provision or otherwise as a matter of law.

See also the Undertakings set forth in the response to Item 9 herein.

**Item 7. Exemption for Registration Claimed.**

Not applicable.

**Item 8. Exhibits.**

---

| | |
|:---|:---|
| **Exhibit<br> Number** | **Description** |
| [4.1](https://www.sec.gov/Archives/edgar/data/2023016/000110465925096003/tm2527800d1_ex3-1.htm) | [Amended and Restated Certificate of Incorporation of Turn Therapeutics Inc. (incorporated by reference from Exhibit 3.1 to the Registrant's Current Report on Form 8-K, filed on October 2, 2025 (File No. 001-42875))](https://www.sec.gov/Archives/edgar/data/2023016/000110465925096003/tm2527800d1_ex3-1.htm) |
| [4.2](https://www.sec.gov/Archives/edgar/data/2023016/000110465925096003/tm2527800d1_ex3-2.htm) | [Amended and Restated By-Laws of Turn Therapeutics Inc. (incorporated herein by reference from Exhibit 3.2 to the Registrant's Current Report on Form 8-K, filed on October 2, 2025 (File No. 001-42875))](https://www.sec.gov/Archives/edgar/data/2023016/000110465925096003/tm2527800d1_ex3-2.htm) |
| [5.1\*](tm2528155d1_ex5-1.htm) | [Opinion of Davis Polk & Wardwell LLP](tm2528155d1_ex5-1.htm) |
| [23.1\*](tm2528155d1_ex23-1.htm) | [Consent of Independent Registered Public Accounting Firm, Withum, Smith & Brown, PC.](tm2528155d1_ex23-1.htm) |
| [23.2\*](tm2528155d1_ex5-1.htm) | [Consent of Davis Polk & Wardwell LLP (included in Exhibit 5.1)](tm2528155d1_ex5-1.htm) |
| [24.1\*](#a_001) | [Power of Attorney (included in signature page hereof)](#a_001) |
| [99.1](https://www.sec.gov/Archives/edgar/data/2023016/000110465925090474/tm2518292d9_ex10-5.htm) | [Turn Therapeutics Inc. 2025 Omnibus Incentive Plan (incorporated by reference from Exhibit 10.5 to the Registrant's Registration Statement on Form S-1, filed on September 24, 2025 (File No. 333-289972))](https://www.sec.gov/Archives/edgar/data/2023016/000110465925090474/tm2518292d9_ex10-5.htm) |
| [99.2](http://www.sec.gov/Archives/edgar/data/2023016/000110465925085850/tm2518292d5_ex10-6.htm) | [Global Health Solutions Inc. 2024 Equity Incentive Plan (incorporated by reference from Exhibit 10.6 to the Registrant's Registration Statement on Form S-1, filed on September 24, 2025 (File No. 333-289972))](http://www.sec.gov/Archives/edgar/data/2023016/000110465925085850/tm2518292d5_ex10-6.htm) |
| [99.3](http://www.sec.gov/Archives/edgar/data/2023016/000110465925085850/tm2518292d5_ex10-7.htm) | [Global Health Solutions Inc. 2018 Stock Plan (incorporated by reference from Exhibit 10.7 to the Registrant's Registration Statement on Form S-1, filed on September 24, 2025 (File No. 333-289972)](http://www.sec.gov/Archives/edgar/data/2023016/000110465925085850/tm2518292d5_ex10-7.htm) |
| [107\*](tm2528155d1_ex-filingfees.htm) | [Filing Fee Table](tm2528155d1_ex-filingfees.htm) |

---

\* Filed herewith.

**Item 9. Undertakings.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The undersigned Registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

(i) To include
 any prospectus required by Section 10(a)(3) of the Securities Act;

(ii) To reflect in the prospectus any
 facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof)
 which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement.
 Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
 offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering
 range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate,
 the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the
 "Calculation of Filing Fee Table" set forth in Exhibit 107 to this Registration Statement;

(iii) To include any material information
 with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information
 in this Registration Statement;

*provided*, *however*, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

**SIGNATURES**

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Westlake Village, California, on October 7, 2025.

---

| | | |
|:---|:---|:---|
| TURN THERAPEUTICS INC. | TURN THERAPEUTICS INC. | TURN THERAPEUTICS INC. |
| By: | /s/ Bradley Burnam | /s/ Bradley Burnam |
|  | Name: | Bradley Burnam |
|  | Title: | Chief Executive Officer |

---

**POWER OF ATTORNEY AND SIGNATURES**

KNOW ALL PERSONS BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Bradley Burnam and Zuraiz Chaudhary, the true and lawful attorneys-in-fact of the undersigned, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Registration Statement and any or all amendments to this Registration Statement, including post-effective amendments, and registration statements filed pursuant to Rules 413 or 462 under the Securities Act of 1933, and to file or cause to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys or attorneys-in-fact or any of them or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons on the dates and in the capacities indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Bradley Burnam | Chief Executive Officer and Director | October 7, 2025 |
| Bradley Burnam | <br> (principal executive officer) |  |
| /s/ Zuraiz Chaudhary | Interim Chief Financial Officer and Chief Accounting Officer | October 7, 2025 |
| Zuraiz Chaudhary | <br> (principal financial officer and principal accounting officer) |  |
| /s/ Andrew Gengos | Director | October 7, 2025 |
| Andrew Gengos |  |  |
| /s/ Dr.Neil Ghodadra | Chief Medical Officer and Director | October 7, 2025 |
| Dr.Neil Ghodadra |  |  |
| /s/ Arthur Golden | Director | October 7, 2025 |
| Arthur Golden |  |  |
| /s/ Dr.Kent Kester | Director | October 7, 2025 |
| Dr.Kent Kester |  |  |

---

## Exhibit 5.1

**EXHIBIT 5.1 and 23.2**

![](tm2528155d1_ex5-1img001.jpg)

Davis Polk & Wardwell LLP

450 Lexington Avenue

New York, NY 10017

davispolk.com

**OPINION OF DAVIS POLK & WARDWELL LLP**

October 7, 2025

Turn Therapeutics Inc.

250 N. Westlake Blvd.

Westlake Village, CA 91362

Ladies and Gentlemen:

We have acted as special counsel to Turn Therapeutics Inc., a Delaware corporation (the "**Company**"), and are delivering this opinion in connection with the Company's Registration Statement on Form S-8 (the "**Registration Statement**") filed with the Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended, for the registration of (i) 3,000,000 shares of the Company's common stock, par value $0.0001 per share ("**Shares**"), authorized for issuance pursuant to the Company's 2025 Omnibus Incentive Plan (the "**2025 Plan**"), (ii) 236,120 Shares subject to outstanding options pursuant to the Company's 2024 Equity Incentive Plan (the "**2024 Plan**") and (iii) 1,508,934 Shares subject to outstanding options pursuant to the Company's 2018 Stock Plan (the "**2018 Plan**" and, together with the 2024 Plan and the 2025 Plan, the "**Plans**"). We, as your counsel, have examined originals or copies of such documents, corporate records, certificates of public officials and other instruments as we have deemed necessary or advisable for the purpose of rendering this opinion.

In rendering the opinion expressed herein, we have, without independent inquiry or investigation, assumed that (i) all documents submitted to us as originals are authentic and complete, (ii) all documents submitted to us as copies conform to authentic, complete originals, (iii) all signatures on all documents that we reviewed are genuine, (iv) all natural persons executing documents had and have the legal capacity to do so, (v) all statements in certificates of public officials and officers of the Company that we reviewed were and are accurate and (vi) all representations made by the Company as to matters of fact in the documents that we reviewed were and are accurate.

On the basis of the foregoing, we are of the opinion that the Shares have been duly authorized and, when to the extent issued pursuant to the Plans upon receipt by the Company of the consideration for the Shares specified therein, will be validly issued, fully paid and non-assessable.

We are members of the Bar of the State of New York and the foregoing opinion is limited to the laws of the State of New York and the General Corporation Law of the State of Delaware.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement.

Very truly yours,

/s/ Davis Polk & Wardwell LLP

Davis Polk & Wardwell LLP

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement on Form S-8 of our report dated June 13, 2025 (which includes an explanatory paragraph relating to the Global Health Solutions Inc dba Turn Therapeutics (the "Company") ability to continue as a going concern), relating to the consolidated balance sheets of the Company as of December 31, 2024 and 2023, and the related consolidated statements of operations, changes in stockholders' equity (deficit), and cash flows for each of the years ended December 31, 2024 and 2023 (the "consolidated financial statements"), and the related notes to the consolidated financial statements of the Company appearing in the Form S-1, as subsequently amended.

We also consent to the reference to us under the caption "Experts" in the Prospectus.

Very truly yours,

---

| |
|:---|
| /s/ WithumSmith+Brown, PC |
| **WithumSmith+Brown, PC**<br> Whippany, New Jersey<br> October 7, 2025 |

---

Page 1 of 1

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Turn Therapeutics Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | Common stock, par value $0.0001 per share, reserved for issuance under the 2025 Omnibus Incentive Plan | 457(a) | 3000000 | $0.0633 | $189900.00 | 0.0001381 | $26.23 |
| 2 | Equity | Common stock, par value $0.0001 per share, pursuant to stock options outstanding under the 2024 Equity Incentive Plan | 457(a) | 236120 | $4.59 | $1083790.80 | 0.0001381 | $149.67 |
| 3 | Equity | Common stock, par value $0.0001 per share, pursuant to stock options outstanding under the 2018 Stock Plan | 457(a) | 1508934 | $2.02 | $3048046.68 | 0.0001381 | $420.94 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $4321737.48  |  | $596.84  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $596.84  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> This Registration Statement on Form S-8 (this "Registration Statement") covers shares of common stock, $0.0001 par value per share ("Common Stock"), of Turn Therapeutics Inc. (the "Registrant") (i) authorized for issuance under the Turn Therapeutics Inc. 2025 Omnibus Incentive Plan (the "Omnibus Plan"), (ii) underlying awards of stock options outstanding under the Global Health Solutions Inc. 2024 Equity Incentive Plan (the "2024 Plan"), (iii) underlying awards of stock options outstanding under the Global Health Solutions Inc. 2018 Stock Plan (the "2018 Plan" and, together with the Omnibus Plan and 2024 Plan, the "Plans") and (iv) pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), any additional shares of Common Stock that may become issuable under the Plans by reason of any stock dividend, stock split or other similar transaction. The shares of Common Stock being registered on this Registration Statement gives effect to the 2-for-1 forward stock split of Common Stock that became effective as of September 30, 2025. Estimated solely for purposes of calculating the registration fee pursuant to Rule 457(h) under the Securities Act. Given that the shares of Common Stock are not traded on an exchange or over-the-counter, the aggregate offering price based on the estimated book value of Common Stock as of June 30, 2025. The book value per share of Common Stock was calculated based on the Registrant's unaudited combined balance sheet as of June 30, 2025. Rounded up to the nearest cent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>2</sup> Estimated in accordance with Rule 457(h) under the Securities Act solely for the purpose of calculating the registration fee on the basis of the weighted-average exercise price of the stock options outstanding under the 2024 Plan. Rounded up to the nearest cent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>3</sup> Estimated in accordance with Rule 457(h) under the Securities Act solely for the purpose of calculating the registration fee on the basis of the weighted-average exercise price of the stock options outstanding under the 2018 Plan. Rounded up to the nearest cent.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---